Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07115004 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
A Phase 3 study of Von Willebrand Disease (VWD), sponsored by Vega Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT07115004: Recruiting Phase 3 study of Von Willebrand Disease (VWD), sponsored by Vega Therapeutics.
NCT07115004 is a Phase 3 study of Von Willebrand Disease (VWD) that is actively recruiting participants, run by Vega Therapeutics. The registered enrollment target is 60 participants, below the 94-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (36% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07115004, a Phase 3 study of Von Willebrand Disease (VWD), is actively recruiting participants, sponsored by Vega Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
Conditions Studied
Interventions
- DRUG VGA039
Study Locations (4)
Arkansas
- Arkansas Children's Hospital - Little Rock
North Carolina
- Science 37, Inc. (Virtual Clinical MetaSite) - Morrisville
Pennsylvania
- Hemophilia Center of Western PA - Pittsburgh
Washington
- Washington Center for Bleeding Disorders - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2028-10 |
| Phase | Phase 3 |
What NCT07115004 shows while recruiting
NCT07115004 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 94-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Von Willebrand Disease (VWD) appearing as the primary indexed condition, and to 1 intervention - of which VGA039 is the first listed.
NCT07115004 reports a single indexed study location in Arkansas, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07115004 about?
NCT07115004 is a clinical study titled "Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)". This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
What is the current status of trial NCT07115004?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-10-15. Estimated completion is 2028-10.
What conditions does trial NCT07115004 study?
This clinical trial studies the following conditions: Von Willebrand Disease (VWD).
What interventions are being tested in trial NCT07115004?
The interventions under investigation include: VGA039 (DRUG).
Who is sponsoring clinical trial NCT07115004?
This trial is sponsored by Vega Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07115004 being conducted?
This trial has 4 study locations across Arkansas, North Carolina, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Disease (VWD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
RECRUITING · Phase 3
-
A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
COMPLETED · Phase 3
-
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
RECRUITING
-
T-TAS® wS Method Comparison
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI